Fateeva Anna, Eddy Kevinn, Chen Suzie
Susan Lehman Cullman Laboratory for Cancer Research, Rutgers University, Piscataway, NJ 08854, USA.
Graduate Program in Cellular and Molecular Pharmacology, Rutgers University, Piscataway, NJ 08854, USA.
Cancers (Basel). 2024 Apr 19;16(8):1571. doi: 10.3390/cancers16081571.
Melanoma is the most aggressive and deadly form of skin cancer due to its high propensity to metastasize to distant organs. Significant progress has been made in the last few decades in melanoma therapeutics, most notably in targeted therapy and immunotherapy. These approaches have greatly improved treatment response outcomes; however, they remain limited in their abilities to hinder disease progression due, in part, to the onset of acquired resistance. In parallel, intrinsic resistance to therapy remains an issue to be resolved. In this review, we summarize currently available therapeutic options for melanoma treatment and focus on possible mechanisms that drive therapeutic resistance. A better understanding of therapy resistance will provide improved rational strategies to overcome these obstacles.
黑色素瘤是最具侵袭性和致命性的皮肤癌形式,因为它极易转移至远处器官。在过去几十年里,黑色素瘤治疗取得了重大进展,最显著的是在靶向治疗和免疫治疗方面。这些方法极大地改善了治疗反应结果;然而,它们在阻碍疾病进展的能力方面仍然有限,部分原因是获得性耐药的出现。与此同时,对治疗的内在耐药性仍然是一个有待解决的问题。在这篇综述中,我们总结了目前可用于黑色素瘤治疗的选项,并重点关注驱动治疗耐药性的可能机制。更好地理解治疗耐药性将提供改进的合理策略来克服这些障碍。